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The Mental Health Biomarker Project aimed to discover case-predictive biomarkers for 
functional psychosis. In a retrospective, cross-sectional study, candidate marker results 
from 67 highly characterized symptomatic participants were compared with results from 
67 gender- and age-matched controls. Urine samples were analyzed for catecholamines, 
their metabolites, and hydroxylpyrolline-2-one, an oxidative stress marker. Blood samples 
were analyzed for vitamin and trace element cofactors of enzymes in catecholamine syn-
thesis and metabolism pathways. Cognitive, auditory, and visual processing measures 
were assessed using a simple 45-min, office-based procedure. Receiver operating curve 
(ROC) and odds ratio analysis discovered biomarkers for deficits in folate, vitamin D and 
B6 and elevations in free copper to zinc ratio, catecholamines and the oxidative stress 
marker. Deficits were discovered in peripheral visual and auditory end-organ function, 
intracerebral auditory and visual processing speed and dichotic listening performance. 
Fifteen ROC biomarker variables were divided into five functional domains. Through a 
repeated ROC process, individual ROC variables, followed by domains and finally the 
overall 15 set model, were dichotomously scored and tallied for abnormal results upon 
which it was found that ≥3 out of 5 abnormal domains achieved an area under the ROC 
curve of 0.952 with a sensitivity of 84% and a specificity of 90%. Six additional middle ear 
biomarkers in a 21 biomarker set increased sensitivity to 94%. Fivefold cross-validation 
yielded a mean sensitivity of 85% for the 15 biomarker set. Non-parametric regression 
analysis confirmed that ≥3 out of 5 abnormally scored domains predicted >50% risk of 
caseness while 4 abnormally scored domains predicted 88% risk of caseness; 100% 
diagnostic certainty was reached when all 5 domains were abnormally scored. These 
findings require validation in prospective cohorts and other mental illness states. They 
have potential for case-detection, -screening, -monitoring, and -targeted personalized 
management. The findings unmask unmet needs within the functional psychosis condi-
tion and suggest new biological understandings of psychosis phenomenology.
Keywords: biomarkers, psychosis, mental illness, model, case detection, case prediction, schizophrenia, 
schizoaffective
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inTrODUcTiOn
The architecture of psychosis is largely unknown, and in everyday 
psychiatric practice, diagnoses are made by assessing observable 
signs and symptoms that are recognized as criteria for diagnoses 
in descriptive-based classification systems. However, clinical 
confidence in the utility of such descriptive diagnostic systems is 
waning in the face of multiple overlapping comorbidities within 
diagnoses. These limitations have increased the call for objec-
tive investigations to find medical models to provide diagnostic 
certainty and explain serious mental illness states (1, 2).
Clinicians are often confronted with complex or uncertain 
presentations of individuals with psychosis. Such individuals 
may not be substance abusing or have a brain disease, yet still 
feature elements of what is called functional psychosis, with some 
symptom features being prominent and others less prominent (3). 
Such presentations may cause a prolonged period of diagnostic 
uncertainty that is stressful for both clinician and patient alike, 
leading to treatment delay and trauma linked to poorer outcomes 
(4, 5). For these reasons, there is a pressing need to discover 
cost-effective, utilitarian biomarkers to identify psychosis with 
certainty. Such an advance would provide a great leap forward for 
clinicians and patients alike (6), would reduce time to treatment, 
and thereby assist recovery and reduce cost-care burden (7, 8). 
Accordingly, the Mental Health Biomarker Project formed an 
experimental plan to assess biochemistry, physiology, symptom, 
and behavioral endpoints for functional psychosis and compare 
outcome data with that from a control sample. The aim was to 
discover, quantify, and explore the association of any discovered 
biomarkers with functional psychosis, as mainly represented by 
diagnoses of schizophrenia and schizoaffective disorder. The plan 
was also to categorize any biomarker findings into a model to 
provide case detection and reduce uncertainty for diagnoses of 
functional psychosis.
As part of this plan, a number of candidate markers were 
selected for investigation of their biomarker status across a 
number of neurobiological levels. Indole–catecholamines and 
their metabolites have been extensively investigated in many 
body fluids, in relationship to psychosis, and there has been 
contrasting findings (9). These and other biochemical markers, 
such as vitamins and mineral enzyme cofactors and intermedi-
ate substances within these indole–catecholamine synthesis and 
metabolism pathways, were selected. Despite the potential of 
these key enzyme cofactors to exert subtle and cumulative effects 
on neurotransmitter synthesis and metabolism (Section S1 and 
Figure S1 in Supplementary Material), they have not been specifi-
cally investigated for their biomarker potential. The relationship 
of these cofactors to the methylation and folate cycles has been 
well summarized by Frankenburg (10) and in other review litera-
ture (11), including that derived from translational findings of 
this project (12).
Clinical experience, pilot study evidence, and implications 
from literature reports (13) guided the choice of candidate 
markers selected for auditory processing and end-organ acuity 
measures. Pilot study findings, literature references, and clinical 
experience with spatial working memory deficits (14) and work-
ing memory deficits (15) in diagnosed patients formed the basis 
of an interest in exploring the potential of candidate markers for 
visual and auditory processing disorder and delay. Reports of 
abnormal preattentive cortical-evoked responses in schizophre-
nia (16) implied that seeking biomarkers of sensory end-organ 
dysfunction in middle ear and visual acuity (17) might also be a 
promising field of biomarker investigation.
MaTerials anD MeThODs
study setting and Design
We undertook a retrospective study using a case–control design 
to discover and quantify biomarkers for functional psychosis 
in schizophrenia and schizoaffective disorder. The study was 
approved by the Queen Elizabeth Hospital Research Ethics 
Committee (No: 2009139), and all protocols and methods used 
in the project conformed to that committee’s relevant regulatory 
standards. Prospective participants were screened and enrolled 
between May 2010 and December 2013 at a large urban hospital, 
the Queen Elizabeth Hospital, Woodville, SA, Australia, and 
two of its satellite mental health clinics in the Western Adelaide 
community catchment area (for further information, see Sample 
Characteristics). Cases were evaluated on the ward, in satellite 
psychiatric outpatient clinics, and some of these elected to be 
assessed in the nearby research institute setting where all control 
participants were assessed. Data relating to this manuscript was 
collected between May 2010 and December 2013 and the study is 
still ongoing. The authors report no conflict of interest at the time 
of undertaking this research or writing this paper.  An interna-
tional patent application was filed in December 2014.
Participants
Recruitment of patients with mainly schizophrenia and 
 schizoaffective disorder allowed sufficient numbers of patients 
with functional psychosis to be obtained within the confines of 
the multiple exclusion criteria described below. This also gave 
scope for exploration of correlative and predictive translational 
relationships between different biomarker variables.
Participants from multi-ethnic backgrounds in an age range 
between 18 and 60  years were enrolled in the study. All par-
ticipants were informed of the goals, assessment procedures, and 
funding of this study. All participants provided written consent. 
Participants were diagnosed, screened for multiple exclusion 
criteria, rated for clinical and subclinical and symptoms, and 
had biological samples taken prior to further neurophysiological 
assessment.
In order to offset severity bias and to allow patients recovery 
time sufficient to understand the conditions of consent, non-
detained hospital cases with functional psychosis were recruited 
and assessed in the expected last week of their admission, as 
judged by their expected discharge date on ward-round consen-
sus opinion. Community cases were not assessed if they were in a 
known state of relapse for any reason. Some cases were diagnosed 
with first-episode psychosis; however, for most cases, diagnosis 
had been sustained and stabilized for a considerable time prior 
to their recruitment. Antipsychotic medication remained stable 
during the assessment period. DSM IV-R criteria-based case 
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diagnoses (18) case diagnoses were made by registrars, confirmed 
by consultants and ward-round consensus, and separately checked 
by DSM IV-R symptom checklist. Individuals with features of 
psychosis, who fully met criteria for selection, were allowed for 
recruitment even if they lacked a firm diagnosis for schizophrenia 
or schizoaffective disorder, in which case a diagnosis of psychosis 
for investigation (psychosis FI) was allocated. However, the 
majority of cases were diagnosed with schizophrenia and schiz-
oaffective disorder, and no difference in consensus diagnostic 
opinion was encountered.
Participants were screened for multiple exclusion criteria 
before entering the study. The aim was to impose sufficient 
exclusion criteria to minimize confounding variables and strip 
psychosis in the case sample as far as possible down to its bare 
functional state, in order to expose which candidate markers had 
strong discrimination and case-detection variables for functional 
psychosis. These exclusion criteria are described in detail below 
and relate to potential confounding factors, such as substance 
abuse, organic causes, and medication effects on candidate mark-
ers. Due to imposition of multiple exclusion criteria, recruitment 
of eligible cases for the study was slow, and a consent rate of only 
one in four eligible participants was found during the recruitment 
process. In this slow, unpredictable recruitment context, random 
sampling of successfully recruited cases was not undertaken. 
Implementation of the exclusion criteria process did, however, 
result in a highly characterized group of patients being enrolled 
in the study. Results on case recruitment and assessment are pro-
vided below and at the beginning of the Results Section “Sample 
Characteristics.”
Exclusion criteria included medication with clozapine and 
olanzapine, which are frequently prescribed medications for 
ward and outpatient clinic patients with repeated admissions 
for psychosis. Together with antihistamines, the following 
medications have prominent histamine-binding effects and so 
were excluded as histamine was a candidate biomarker. Patients 
taking antipsychotic agents, such as zuclopenthixol, modecate, 
amisulpride, quetiapine, and risperidone, were included. Persons 
on mood stabilizing medications were allowed. Persons with 
active or unremitted use of alcohol or other substance abuse 
were excluded, since this can confound neurotransmitter results. 
Persons with organic cerebral damage, as evidenced by a clinically 
documented, investigated, or descriptive history of hospitalized 
head injury, unconsciousness, or central nervous system disease, 
were also excluded, as were persons with upper respiratory tract 
infections, middle ear congestion, or known sensory disability. 
Persons with extrapyramidal signs in ocular, arm, or hand 
muscles (19) were excluded prior to consent. Persons receiving 
active vitamin therapy were also excluded due to the inclusion 
of vitamins as candidate markers. It was not possible to exclude 
smoking and have any chance of patient recruitment.
Control participants were age- and sex-stratified based upon 
patient recruitment data, and they were then recruited by the 
Population Research and Outcomes Studies (PROS) Unit of 
the University of Adelaide. Eligible participants were randomly 
phone recruited from participants in the North West Adelaide 
catchment area associated with the Department of Medicine at 
the Queen Elizabeth Hospital. Persons with diagnosed mental 
illness, disorientation, documented or anecdotal history of 
substance abuse, head injury, visual or hearing disability, learn-
ing disability, movement disorder, or taking antihistamine 
medication or vitamin supplementation similar to candidate 
markers were excluded. No control participant had a diagnosis 
of schizophrenia or any DSM-diagnosable mental illness but was 
rated for subclinical symptoms. Further information regarding 
control recruitment, characteristics, and assessment is provided 
at the beginning of the Results Section “Sample Characteristics.”
Outcome Measures
All study participants were assessed in a real-world setting by 
a psychiatric trained assessor who was not blind to their study 
status. Ratings for cases were undertaken by ward registrars and 
consultants and for controls by a single psychiatrically trained 
researcher. All raters were blind to index laboratory and sensory 
processing test results at the time of rating. All participants were 
separately rated on standardized clinical measures as outlined, 
with citations, in Section S2 in Supplementary Material. These 
measures included the Clinical Global Impression of Severity 
(CGI), Global Assessment of Function (GAF), and Social and 
Occupational Functioning Assessment Scale (SOFAS). Clinical 
and subclinical symptoms were rated using the Brief Psychiatric 
Rating Scale (BPRS), which has many symptom overlaps with 
those within the Positive and Negative Syndrome for schizophre-
nia (PANSS); therefore, symptom scores were amalgamated in 
the interest of reducing assessment time. The symptom intensity 
rating (SIR) for each symptom (designated 1–7) was summated to 
give a symptom-intensity (SIR) index for each participant, which 
was taken as a measure of clinical severity. Additional outcome 
measures were collected for hospitalization frequency and dis-
ability pension status since these measures relate to community 
cost-care burden of psychosis management. Degree of stress was 
not specifically documented within the research protocol; how-
ever, the intensity of three BPRS/PANSS stress-related symptom 
ratings for anxiety, tension, and dissociation were analyzed for the 
strength of their Spearman’s correlates in relationship to biomark-
ers findings. Information was gathered on some risk predictors 
for schizophrenia or schizoaffective disorder, such as presence or 
absence of a family history of schizophrenia, depression or mania, 
developmental disorder (DD) history, or learning disorder (LD) 
history. Information was also gathered on history of ear infection 
and premorbid subclinical (non-concussed) head injury.
specimen collection and Biochemical 
assays
Candidate biochemical markers were selected for reasons broadly 
outlined in Section “Introduction.” Collection methods for these 
candidate markers are documented (with citations) in Section S3 
in Supplementary Material of this manuscript. Specimens col-
lected from blood were for assay of vitamin B6 (20, 21), vitamin 
B12, red cell folate and plasma homocysteine (22–28), serum 
copper (29), serum ceruloplasmin (30), red cell zinc (31), serum 
histamine (32), and serum methyltetrahydrofolate reductase 
(MTHFR 677 C → T) gene polymorphism, which has potential 
influence on transfer of methyl groups to the methylation cycle 
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(Section S1 in Supplementary Material) via folate (12, 33). 
Vitamin D was also selected because of its epidemiological link 
with schizophrenia (34). Urine assay for levels of creatinine, 
dopamine (DA), noradrenaline (NA), adrenaline (AD), and two 
of their metabolites [homovanillic acid (HVA) and methoxyhy-
droxymandelic acid (MHMA)], as well as the serotonin metabolite 
5-hydroxyindoleacetic acid (5-HIAA), were undertaken. Urine 
was also collected for levels of hydroxyhemopyrroline-2-one 
(HPL), which is a theoretical indicator of oxidative stress and 
disturbed porphyrin synthesis in schizophrenia (35). Urine was 
collected early in the morning with the patient in a fasting, rested 
state. The separation time between blood collection and urine 
collection was 2 h. As outlined in Section S3 in Supplementary 
Material, biological sample collection, transport, and storage 
was standardized by protocol, and testing of all samples was 
conducted by independent commercial laboratories that were 
blind to the case or control status of the participant.
sensory Processing assessments
Sensory processing assessments were made after clinical exclu-
sion of extrapyramidal side effects affecting vision, neck, or hand 
coordination (Sections  S4 and S5 in Supplementary Material) 
(19). Visual assessments using the participant’s usual glasses were 
conducted after an alternate-cover-test to exclude visual fixation 
disparity [phoria (36)]. Assessment consisted of binocular near 
and distance visual acuity, visual attention span and speed, and 
accuracy of visual processing (Section S4 in Supplementary 
Material). Assessments were undertaken at a time separated 
from blood and urine collection by a minimum of 2 h and within 
a maximum time of 4  days. Assessments were performed by a 
single psychiatrically trained researcher. Assessors were not 
blinded to participant status because the residual symptoms of 
psychosis make this impractical; however, assessors were blind 
to laboratory results.
Auditory processing assessments (Section S5 in Supplementary 
Material) were conducted in a quiet room (ambient noise level 
20 dB), preceded by examination of the external auditory meatus 
to exclude obvious pathology or sebum obstruction. Auditory 
acuity characteristics were examined between 250 and 4000 Hz to 
determine air-bone conduction gaps of >10 Hz or threshold shift 
abnormalities >1000  Hz and laterality differences. Equipment 
used in sensory processing testing is shown in Section S6 in 
Supplementary Material (Figures  S2 and S3 in Supplementary 
Material).
Middle ear acoustic reflexes were directly measured as 
documented in Section S7 in Supplementary Material. Middle ear 
compliance and sound conductance across the middle ear cham-
ber gave parameters for ear canal volume at threshold auditory 
response. Peak middle ear pressure at threshold auditory response 
and the gradient of the middle ear pressure are parameters that 
reflect the response of the tympanic muscle as it contracts as 
sound enters the ear. The effect of tympanic contraction is then 
relayed via a chain of ossicle bones across the middle ear to the 
stapes muscle. Stapes contraction is effected by the stapes muscle 
applying the handle of the stapes bone to the oval window of the 
cochlea, which has the effect of dampening sound as it enters the 
cochlea. The strength and timing of the stapes reflex response was 
directly measured in order to ascertain the alacrity or delay of 
this middle ear sound-dampening mechanism. Where repeated 
testing was necessary, an interval of 30  s or more was allowed 
between trials in order to prevent error from muscle fatigue.
statistical analysis
Power analysis for this study (37) is outlined in Section S8 in 
Supplementary Material. The principals behind the processes 
that comprise formation of the 15 and 21 biomarker sets and their 
respective domains, regression analysis for these, model validation 
procedures, and the relationship of findings to functional outcome 
measures and stress-related symptoms are outlined below.
Sample characteristics analysis was conducted using XLSTAT 
(Addinsoft) (38) for descriptive statistics and STATA software 
(39). Variable distributions were also analyzed by Kolmogorov–
Smirnov analysis; associations were tested using Pearson 
chi-square, likelihood ratio, and Fishers exact test. Independent-
sample Mann–Whitney U test (40) was used to detect sample dif-
ference where there was lack of normal distribution in continuous 
candidate variables across groups. Data characteristics related to 
risk factors (Section S10 in Supplementary Material) and medica-
tion profile for cases were also analyzed using STATA (Section 
S11 in Supplementary Material).
Receiver operating characteristic analysis (41, 42) was carried 
out using XLSTAT software (38) in order to discover biomarker 
variables and examine their characteristics. With respect to the 
area under the ROC curve (AUC), this measure indicates an 
outcome variable’s ability to discriminate between cases and 
control outcome measures. When this discrimination is good, 
a curve with a large area underneath it is achieved. An AUC 
of 0.5–0.7 represents poor discrimination, 0.7–0.8 acceptable 
discrimination, 0.8–0.9 excellent discrimination, and >0.9 out-
standing discrimination. A high sensitivity means that a test only 
rarely misses classifying a person with schizophrenia/psychosis 
as having such diagnosis, and therefore, the test has utility as a 
diagnostic method. A high specificity means that a test only rarely 
designates a person with schizophrenia/psychosis as being free 
of that diagnosis, so the test therefore has utility as a diagnostic 
exclusion, screening tool. Sensitivity and specificity are consid-
ered acceptable at ≥85% and ideal at ≥90%. Missing data were 
imputed using XLSTAT (38). Diagnostic associations for ROC 
variables were also analyzed for odds ratio (OR) (43)1, where OR 
≥2 was considered important.
Discovered ROC analysis variables, their parameters, and 
OR values were divided into domains based upon their func-
tion. Depending upon their unique ROC analysis cutoff point, 
variables resulting from ROC analyzes (ROC variables) in 
each different functional domain were scored dichotomously 
for abnormality and underwent ROC analysis again to obtain 
a threshold abnormal ROC score for each separate functional 
domain. These domain scores were tallied and the ROC process 
repeated again to derive ROC parameters for the whole biomarker 
model set and to obtain a cutoff threshold of abnormality for case 
detection using the whole model set. In this way, ROC variables 
1Available from: http://easycalculation.com/statistics/odds-ratio.php
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within each of the segregated domains and their cutoff ranges 
were combined into an overall ROC Model from which could be 
determined a case-detection threshold and reference standard for 
diagnostic accuracy. Comparison was made between missing data 
imputed and non-imputed data outcomes for these biomarker 
sets of discovered variables. Compound outcome variables of 
theoretical interest were also examined by ROC analysis and 
the theory behind their selection is outlined in Results Section 
“Characteristics of Residual and Compound ROC Variables.”
Regression analysis was undertaken to identify the predictive 
risk of schizophrenia or psychosis related to number of abnor-
mally scored domains, using logistic regression and Lowess 
locally weighted non-parametric regression analysis (43).
Spearman’s correlation analysis (38) was used to investigate 
compound and other ROC variables of interest and to examine 
the contribution of stress to the results. Specifically, appraisal 
of the relationships of stress symptoms for anxiety, tension and 
dissociation to ROC variables discovered, was carried out by 
Spearman’s analysis.
Model Validation
Model validation (see Model Validation) was determined by 
(A)–(C), below:
 (A) Case discrimination strengths for individual variables and 
tallied sets of variables were provided by AUCs, and the 
accuracy index provided by XLSTAT.
 (B) Fivefold cross-validation process (44, 45). In this process, 
cases and controls were separately randomized into five 
groups and biomarker set(s) built again using four fifths of 
the data as a “training set” to be validated against the other 
fifth of the data as a “test set.” Five separate iterations were 
undertaken where each group was used as a validation 
sample only once, and the other four groups were used as a 
calibration sample in each fold. As a result, none of the data 
used to construct each biomarker set were used to validate 
it. Then, by comparing calibration (AUC) and prediction 
accuracy [using STATA software (40)], with parameters 
derived from the original 15 biomarker set, any optimism 
arising from a small sample with case–control modeling can 
be adjusted.
 (C) As an initial form of content validity for the model, 
Spearman’s correlation was used to identify the relation-
ships between the domains of the model and functional 
measures that were external to the model parameters (see 
Examination of Stress-Related Symptoms in Relationship to 
Risk-Predictor Variables). These functional measures were 
for severity (SIR and CGI), disability (GAF), and cost/sup-
port burden as determined from disability support pension 
(DSP) requirement and hospital admission frequency.
resUlTs
The total North West population number for the hospital and 
community clinics was estimated at 22,000 (46). Imposition of 
multiple exclusion criteria (see Participants) restricted eligible 
cases to 370, and only 25% of these consented to participation. 
This high refusal rate resulted in 89 consenting cases, of which 
7 did not reach assessment due to declining mental state and 15 
were excluded due to the confounding factor of SSRI and SNRI 
medication. This was due to detection of an interesting masking 
effect of SSRI and SNRI medication on catecholamine levels, 
sensory processing performance, and middle ear outcome meas-
urements. Due to the above factors, case enrollment in the study 
was slow; therefore, random sampling of recruited cases was not 
undertaken. Number of cases in the final analysis was 67, which 
still included 3 cases treated with a SSRI.
The control sample was drawn from an available sample num-
ber of 2489 (47). After stratification of patients for age- and sex 
matching with control participant extraction, randomization and 
imposition of recruitment exclusion criteria, and a low consent 
rate of 25%, a total of 72 control participants were recruited. Five 
of these were excluded due to failure to meet exclusion criteria on 
face-to-face history taking and assessment. No control participant 
had a diagnosis of schizophrenia or any DSM-diagnosable mental 
illness but was rated before assessment for reported and observed 
subclinical symptoms in a real-world setting, by a psychiatric 
trained assessor who was not blind to their study status.
sample characteristics
Final data analysis was based on data from 67 cases and 67 control 
participants. Section S12 in Supplementary Material records the 
level of missing data, which was 1.5% for the laboratory-derived 
variables, 8.2% for the visual assessment variables, and 7.5% for 
the auditory assessment variables. Table 1 presents the breakdown 
characteristics of participants according to their gender age, diag-
nosis BMI, age of onset, duration of illness, and intensity of rated 
symptoms (SIR). Secondary tables containing data distribution 
analysis and chi-square analysis are included in Section S10 in 
Supplementary Material. Difficulty was encountered recruiting 
sufficient young persons to volunteer as controls; so, the mean 
age of the control population is 5  years older than the patient 
sample, and this difference was detected on independent-sample 
Mann–Whitney U test (P =  0.006). The Kolmogorov–Smirnov 
sample distribution analysis for BMI (P =  0.000) showed it to 
be non-normally distributed. An independent-sample Mann–
Whitney U test failed to detect significant statistical difference 
between cases and controls for BMI.
Data characteristics related to risk factors for functional 
psychosis collected within the history protocol are also given 
in Section S10 in Supplementary Material. A list of psychiatric 
medications for participants is included in Section S11 in 
Supplementary Material.
rOc and Odds ratio results
Fifteen biomarkers were selected firstly for their strength of 
discrimination on ROC analyses but also for their sensitivity or 
specificity (Table 2). Biomarker findings were for elevated urine 
levels of DA, NA, AD, and the urine oxidative stress marker 
hydroxypyrroline-2-one/creatinine, adjusted for creatinine levels 
(HPL/creatinine). Deficit-related biomarkers were discovered for 
red cell folate, pyridoxal-5′-phosphate coenzyme form of activated 
B6, and the activated 25-OH form of serum vitamin D. Serum 
TaBle 1 | sample characteristics (se).
characteristic schizophrenia schizoaffective 
psychosis
Psychosis Fi cases controls Total participants
n Mean se n Mean se n Mean se n Mean se n Mean se n Mean se
Age 33 40.7 2.0 30 40.8 1.9 4 37.3 7.4 67 40.5 1.3 67 45.7 1.4 134 43.1 1.0
Age of onset 31 23.9 2.0 27 22.5 1.5 3 32.7 10.1 61 23.7 1.3 0 61 23.7 1.3
Duration of illness (DOI) 31 16.5 1.9 27 18.0 2.3 3 8.0 1.0 61 16.8 1.4 0 61 16.8 1.4
Symptom intensity rating (SIR) 33 113.8 5.7 30 94.4 5.7 4 119.5 14.8 67 105.4 4.0 67 42.8 0.3 134 74.1 3.4
Body mass index (BMI) 23 31.1 2.3 27 29.6 1.4 3 25.8 1.2 53 30.0 1.2 66 26.7 0.6 119 28.2 0.6
Right hand dominance % 32 92.1 3.0 29 94.5 2.4 4 82.5 17.5 65 92.6 2.1 67 93.1 1.7 132 92.8 1.3
Urine creatinine (mmol/L) 33 8.8 0.9 29 9.3 1.2 4 12.3 5.1 66 9.2 0.7 67 9.5 0.7 133 9.3 0.5
5-Hydroxyl indole acetic acid 
(5-HIAA)
33 4.6 1.4 29 3.3 0.8 4 9.5 4.8 66 4.3 0.8 67 1.6 0.1 133 2.9 0.4
Plasma homocysteine (μmol/L) 33 10.5 0.4 29 9.5 0.5 4 9.3 1.4 66 10.0 0.3 66 9.5 0.3 132 9.7 0.2
Red cell acetylcholine esterase 
(U/gb Hb)
29 38.3 0.9 29 41.6 1.2 3 37.3 1.9 61 39.8 0.7 67 39.6 0.7 128 39.7 0.5
Hearing threshold (dB) 31 548.4 27.0 23 587.0 67.8 3 500.0 0.0 57 561.4 30.8 60 550.0 19.5 117 555.6 18.0
Visual threshold of near vision 32 6.5 0.6 26 6.0 0.7 3 8.0 3.0 61 6.3 0.5 67 5.2 0.1 128 5.7 0.2
schizophrenia schizoaffective 
psychosis
Psychosis Fi cases controls Total participants
n % n % n % n % n % n %
Sex
Female 12 36.4 16 53.3 2 50.0 30 44.8 34 50.7 64 47.8
Male 21 63.6 14 46.7 2 50.0 37 55.2 33 49.3 70 52.2
Persons 33 100.0 30 100.0 4 100.0 67 100.0 67 100.0 134 100.0
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B12 had lower discrimination capacity but higher specificity, and 
the ratio of percentage of free copper to red cell zinc also reached 
biomarker capacity. Within the sensory processing spectrum of 
outcome variables, significant ROC variables were discovered 
for visual (symbol) attention span and threshold visual speed of 
processing performance with respect to norm for age, expressed 
in terms of a per cent value. Though binocular distance vision 
was relatively impaired in cases versus control, outcome measures 
representing impaired long distance acuity for visual informa-
tion from the right eye was discovered to have biomarker status. 
Reverse digit span (which measures auditory or verbal working 
memory) and speed of auditory processing, at threshold hear-
ing level, expressed as percentage of norm for age was a further 
biomarker. A significant ROC variable for the competing words 
listening task performance (expressed as a percentage of norm 
results for age), is a notable result as this is a dichotic listening 
test that measures cross-hemispheric ability to attend to auditory 
information presented simultaneously to both ears.
Six biomarkers were discovered on middle ear performance 
testing. These included biomarkers for tympanic and stapes reflex 
muscle contraction, threshold percentage length of the base of the 
stapes reflex divided by the total duration of the reflex (a measure 
of the strength of the stapes reflex during its maximal period of 
contraction), threshold stapes amplitude projected (alternative 
measure of stapes contraction strength), threshold time to offset 
of the stapes reflex contraction divided by the base length (gives 
a measure of acoustic reflex decay), threshold ear canal volume 
(as measure of middle ear integrity), threshold peak middle ear 
pressure, and threshold gradient middle ear pressure (related to 
tympanic reflex strength), as outlined in Table 3. Raw outcome 
measures relating to these ROC variables can be quickly meas-
ured on clinical assessment; however, this requires more expen-
sive equipment (Section S7 in Supplementary Material), greater 
clinical expertise and more data transformation into meaningful 
measures than that required for the previously described 15 
ROC variables above. Also, their addition to the 15 biomarker 
set did not add discrimination strength to the overall set of 21 
biomarkers, though it did impart marginally higher sensitivity 
for psychosis risk-prediction and case-detection purposes. For 
these reasons, the six middle ear biomarkers are considered 
to have potential utility for case detection when an individual 
has symptoms that are highly suggestive of psychosis but their 
more-easily assessed 15 biomarkers do not reach threshold for 
case detection of functional psychosis.
When ROC variables were dichotomously scored for abnor-
mality against their threshold cutoff value and these scores were 
tallied and ROC analyzed again, a threshold of abnormality 
for each domain was determined. Then, in a similar manner, 
these domain scores were tallied and ROC analyzed for the 
15 and 21 biomarker sets, respectively, to obtain a threshold 
number of abnormal domains required for case detection, 
together with their ROC parameters (Tables 2 and 3) (Section 
TaBle 2 | Fifteen biomarker set with odds ratio.
Domain name 
and number
rOc set no. rOc variables no. 
Obs
aUc sens sPec PPV nPV % risk of 
rejecting 
ho
rOc  
P value
Odds  
ratio+
Odds ratio 
P value
accuracy
1. Visual 1 Low visual span 126 0.862 0.831 0.821 0.021 0.999 0.01 <0.0001 22.46 <0.0001 0.8254
2 High visual speed 
of processing 
discrepancy (% of age)
122 0.875 0.909 0.731 0.015 0.999 0.01 <0.0001 27.22 <0.0001 0.8115
3 Poor distance vision 
on right
128 0.597 0.475 0.851 0.014 0.997 0.01 <0.0001 5.17 0.0001 0.6719
2. Auditory 4 Low reverse digit span 127 0.810 0.900 0.552 0.009 0.999 0.02 0.000 11.1 <0.0001 0.8707
5 High competing words 
discrepancy (% of 
pass score) (represents 
dichotic listening 
disorder)
124 0.799 0.759 0.773 0.015 0.999 0.01 <0.0001 10.69 <0.0001 0.8362
6 High auditory speed 
of processing 
discrepancy (% of age)
121 0.874 0.745 0.879 0.027 0.999 0.01 <0.0001 21.23 <0.0001 0.6810
3. 
Catecholamine
7 High dopamine 133 0.702 0.379 0.940 0.028 0.997 0.01 <0.0001 9.60 <0.0001 0.6617
8 High noradrenaline 133 0.851 0.742 0.881 0.027 0.999 0.01 <0.0001 21.25 <0.0001 0.8120
9 High adrenaline 133 0.844 0.758 0.821 0.019 0.999 0.01 <0.0001 14.32 <0.0001 0.7895
4. Oxidative 
stress
10 High (HPL/creatinine)a 
(oxidative stress 
domain)
133 0.696 0.697 0.642 0.009 0.998 0.01 <0.0001 4.12 <0.0001 0.6692
5. 
Biochemistry–
nutrition
11 High free copper to 
zinc ratio
133 0.611 0.470 0.746 0.008 0.997 2.19 0.022 2.60 0.0104 0.6090
12 Low B6 activation 129 0.638 0.800 0.484 0.008 0.997 0.17 0.002 3.75 0.0009 0.6434
13 Low red cell folate 133 0.654 0.591 0.716 0.009 0.997 0.10 0.001 3.64 0.0005 0.6541
14 High serum B12 (80% 
CI)
134 0.565 0.373 0.761 0.007 0.996 18.56 0.186 1.89 0.0933 0.5672
15 Low vitamin D 132 0.651 0.462 0.791 0.010 0.997 0.12 0.001 3.24 0.0026 0.6288
Fifteeen biomarkers in five for schizophrenia and schizoaffective disorder. All values reported at 95% confidence interval unless otherwise stated.
ROC, receiver operating curve; No Obs, number of observations; AUC, area under receiver operating curve (ideally >0.6); SENS, sensitivity; SPEC, specificity; pre-adjusted odds 
ratio + prior to division by 3, P value for odds ratio at 95% confidence interval; % RR-Ho, percentage risk ratio for null hypothesis (ideally <0.10), HPL, urinary hydroxyhemopyrroline-
2-one.
aCatecholamines did not require imputation.
TaBle 3 | additional six middle ear rOc variables, comprising the full 21 biomarker set with odds ratio.
Domain name 
and number
set 
number
rOc variables no. 
Obs
aUc sens sPec PPV nPV % risk of 
rejecting ho
rOc  
P value
Odds 
ratioa
Odds ratio 
P value
accuracy
6. Middle ear 
(supplementary 
domain)
16 High threshold ear canal volume 123 0.603 0.367 0.825 0.006 0.997 0.01 <0.0001 2.74 0.0181 0.6016
17 Low threshold peak middle ear 
pressure
124 0.617 0.700 0.484 0.006 0.997 0.04 0.000 2.19 0.0369 0.5887
18 High threshold gradient middle ear 
pressure (90%)
124 0.580 0.370 0.891 0.013 0.997 6.74 0.0674 3.77 0.0064 0.6129
19 High threshold stapes amplitude 
projected
123 0.626 0.583 0.651 0.007 0.997 0.29 0.003 2.61 0.0099 0.6179
20 Low threshold time to offset/base 
length
122 0.659 0.683 0.613 0.008 0.998 0.01 0.001 3.42 0.0013 0.6475
21 High threshold percentage base 
length/duration
122 0.657 0.583 0.774 0.120 0.998 0.14 0.001 4.80 0.0001 0.6803
Twenty-one biomarkers in a total of six domains for schizophrenia and schizoaffective disorder. All values reported at 95% confidence interval unless otherwise stated.
ROC, receiver operating curve; No Obs, number of observations; AUC, area under receiver operating curve (ideally >0.6); SENS, sensitivity; SPEC, specificity; pre-adjusted odds 
ratio (prior to division by 3), P value for odds ratio at 95% confidence interval; % RR-Ho, percentage risk ratio for null hypothesis (ideally <0.10); HPL, urinary hydroxyhemopyrroline-
2-one.
aMiddle ear domain and catecholamine domain did not require imputation.
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S12 in Supplementary Material). The 15 biomarker set (with 5 
domains) had a specificity range of 80–96 (mean 91%) and a 
sensitivity range of 69–90 (mean 82%), for identification of the 
relevant psychosis conditions, at the 95% level of significance. 
ROC variables for elevated levels of NA, AD, reduced visual 
span, visual speed of processing variables, and competing 
words deficit (dichotic listening disorder) show high sensitivity 
and/or high specificity for the detection of schizophrenia and 
TaBle 4 | Parameters and pathological cutoff values for six functional domains of biomarkers for functional psychosis.
Domain number and name no. rOc 
variables  
per domain
no. 
Obs
aUc sens sPec PPV nPV % risk of 
rejecting 
ho
rOc  
P value
Odds 
ratio
Odds 
ratio  
P value
accuracy
1. Visual domain 3 120 0.915 0.849 0.881 0.031 0.999 0.010 <0.0001 41.48 <0.0001 0.8667
2. Auditory domain 3 119 0.891 0.868 0.818 0.021 0.999 0.01 <0.0001 29.57 <0.0001 0.6016
3. Catecholamine domain* 3 133 0.859 0.848 0.746 0.015 0.999 0.01 <0.0001 16.47 <0.0001 0.9790
4. Oxidative stress (HPL/creatinine) 1 133 0.696 0.697 0.642 0.009 0.998 0.01 <0.0001 4.12 <0.0001 0.6692
5. Biochemistry–nutrition 5 126 0.797 0.548 0.875 0.019 0.998 0.39 0.001 8.5 <0.0001 0.7143
Combined 15-set, 5 domain
(Not imputed), cut off ≥3 domains 15 107 0.952 0.841 0.905 0.038 0.999 0.01 <0.0001 50.21 <0.0001 0.8707
(Not imputed) cut off ≥4 domains 107 0.952 0.659 0.984 0.158 0.998 0.01 <0.0001 119.867 <0.0001 0.8352
(Imputed), cut off ≥3 domains 116 0.951 0.824 0.908 0.039 0.999 0.01 <0.0001 45.89 <0.0001 0.8362
(Imputed), cutoff ≥4 Domains 116 0.951 0.647 0.985 0.160 0.998 0.01 <0.0001 117.333 <0.0001
6. Middle ear domain (supplementary)* 6 120 0.738 0.48 0.520 0.130 0.997 0.03 <0.0001 4.28 0.0001 0.6583
Combined 21 set, 6 domain (imputed) 
with middle ear domain cutoff at 3/6 
domains
21 108 0.954 0.940 
(0.830–0.985)
0.833 
(0.689–0.892)
0.022 1.0 0.01 <0.0001 66.93 <0.0001 0.740
All values reported at 95% confidence interval unless otherwise stated. ROC, receiver operating curve; No Obs, number of observations; AUC, area under receiver operating curve 
(ideally >0.6); SENS, Sensitivity; SPEC, specificity; pre-adjusted ODDS ratio + prior to division by 3, P value for odds ratio at 95% confidence interval; % RR-Ho, percentage risk ratio 
for null hypothesis (ideally <0.10), HPL, urinary hydroxyhemopyrroline-2-one. 
Bold font for parameters for the combined imputed and non-imputed 15 biomarker set and the combined 21 biomarker set.
*Middle ear domain and catecholamine domain did not require imputation.
FigUre 1 | rOc curves for the 21 biomarker set.
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schizoaffective forms of functional psychosis. Auditory speed 
of processing variables showed both high sensitivity and high 
specificity.
The relative strengths of the functional domains represented 
within the 21 biomarker set are demonstrated in Figure 1.
When domain scores were tallied and the ROC process 
repeated again to derive a threshold of abnormality for the whole 
15 biomarker (5 domains) model set (Table 4), the threshold of 
diagnostic detection was found to be reached at ≥3 abnormal 
domains. The unimputed 15 biomarker set of 5 domains had 
good case discrimination (AUC =  0.952) with 84% sensitivity 
and 90% specificity for case detection and screening purposes. 
This means that 15 biomarkers in 5 domains were able to identify 
84% of symptomatic participants as having schizophrenia or 
schizoaffective psychosis and 90% of asymptomatic participants 
as having no schizophrenia or schizoaffective psychosis. With 
imputed values, the 15 biomarker set had an AUC of 0.951, a 
mean specificity of 91% (range of 81–96%), and a lower mean 
sensitivity of 82% (range of 69–90%). Its combined sensitivity 
and specificity was 1.836, and sensitivity was 85% on model 
cross-validation.
Inclusion of the middle ear biomarkers to form a set of 21 bio-
markers, in 6 domains of inquiry, raised mean sensitivity to 0.94 
(94%) for a range of 0.83–0.96 and identified 96% of symptomatic 
participants as having a diagnosis of schizophrenia or schizoaf-
fective psychosis, with a combined sensitivity and specificity of 
1.771. Despite this, the overall specificity of the imputed 21 bio-
marker set was only 83% (range 0.70–0.89), reducing its screening 
capacity. Therefore, it has supplementary utility if a diagnosis is 
suspected from a patient’s clinical profile, yet 15 biomarkers alone 
are not definitive for case detection of functional psychosis.
characteristics of residual and 
compound rOc Variables
A number of ROC variables were not included in the 15 and 21 
biomarker sets.
ROC-related parameters of three compound variables did 
not add more strength to discrimination, sensitivity, specificity, 
or predictive parameters within the 15 and 21 biomarker sets 
selected. These compound variables were for DA  ×  5HIAA 
(n = 133, Spearman’s rho = 0.420, P = 0.000, OR = 1.00, P = 0.000, 
AUC =  0.745 P <  0.0001), NA/MHMA (n =  133, Spearman’s 
rho =  0.50, P =  0.000, OR =  1.00, P =  0.00, AUC =  0.7915, 
P < 0.0001), and AD/MHMA (n = 130, rho = 0.495, P = 0.000, 
n =  133, OR =  1.92, P =  0.000, AUC =  0.786, P <  0.0001). 
Nevertheless, high correlations of these compound biomark-
ers with caseness cannot be ignored in terms of their possible 
FigUre 2 | rOc curves for variables residual to the 21 biomarker set. FigUre 3 | rOc curves for  risk factors.
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dynamic implications within the nutritional biochemistry under 
investigation and their potential meaning is discussed in Section 
“Biochemistry and Nutrition.”
Though histamine  +  elevated noradrenalin (n  =  134, 
Spearman’s rho  =  0.59, P  =  0.000, OR  =  1.13, P  =  0.000, 
AUC = 0.837, P < 0.0001) produced a standout AUC, this was 
not better than that for the single NA biomarker and histamine 
biomarker, alone (see Figure  2), which only produced a low 
discrimination ROC (n = 133, AUC = 0.576, P < 0.0001). Other 
selected markers that produced ROCs with poor discrimination 
capacity (AUC  >  0.5, but <0.6, Figure  2) were for MTHFR 
C667T polymorphism (n =  134, AUC =  0.5109, P =  0.000), 
plasma homocysteine (n =  132, AUC =  0.557, P =  0.049, at 
75% confidence level), and MHMA (n =  133, AUC =  0.678, 
P = 0.000, at 65% level of confidence). It was, however, notable 
that the elevated NA biomarker correlated highly to high NA/
MHMA biomarker (n  =  133, rho  =  0.673, P  =  0.0000) on 
Spearman’s correlation analysis, as did the AD biomarker with 
the AD/MHMA biomarker (n130, rho =  0.712, P =  0.0000). 
The serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA) 
ROC (n = 133, AUC = 0.677, P = 0.000), was only significant 
at 70% confidence level, despite its independent-sample Mann–
Whitney U test detecting a distribution difference between cases 
and controls (see ROC and Odds Ratio Results). Other sensory 
variables which failed to produce ROC discrimination capacity 
were outcome measures for auditory gap detection and auditory-
figure ground tests within the SCAN test for auditory processing 
disorder and outcomes for near vision using the Sussex near 
vision test (Section S4 in Supplementary Material).
Collateral information gathered from participants on 
presence or absence of history for some risk predictors for 
schizophrenia or schizoaffective disorder were dichotomously 
scored and those that yielded significant case-discrimination 
ability were as follows: developmental disorder (DD) history 
(n =  103, AUC =  0.764, P =  0.000), LD history (n =  13,434, 
AUC = 0.731, P = 0.000), and subclinical premorbid head injury 
(CHI) (n =  129, AUC =  0.614, P =  0.001). Though a clinical 
history of ear infection did not yield a significant ROC and 
participants with significant auditory conduction disorder were 
excluded from participation, audiogram score for subclinical air/
bone conduction discrepancy indicated that subclinical inner 
ear pathology is a factor of significance in functional psychosis 
(n = 128, AUC = 0.601, P = 0.010) (Figure 3). Given that a family 
history of mental illness was not an exclusion factor for recruit-
ment of controls in our study, the fact that a positive family 
history yielded a low, insignificant AUC (n = 130, AUC = 0.539, 
P = 0.086) for our sample population is not surprising but high-
lights the significance of our other ROC findings. We also noted 
(Section S10 in Supplementary Material) that the ROC variable 
derived from scoring for inflammatory or sclerosis signs on 
tympanic membrane otoscopy was 80% related to the diagnosis 
of schizoaffective psychosis. Furthermore, subclinical premorbid 
head injury or a premorbid history of abnormal otoscopy or 
abnormal bone conduction findings were 100% related to the 
diagnosis of functional psychosis for investigation (psychosis 
FI) – this being a diagnostic category allocated to three patients 
in the study who met criteria for exclusion factors, but for whom 
no discrete psychosis diagnosis had been assigned.
regression analysis to Determine case-
Detection Threshold and Predictive risk
Logistic and non-parametric regression results for the number of 
abnormally scored domains are shown in Table 5. This analysis 
confirmed that ≥3 abnormally scored domains predicted (>50%) 
risk of case-detection threshold for the 15 biomarker set, while 4 
abnormally scored domains predicted 88% risk of diagnosis and 
100% certainty of diagnosis was reached when all 5 domains were 
abnormally scored.
Model Validation
Biomarker set validation procedures are described in Materials 
and Methods Section “Model Validation” and results are pre-
sented in sequence of method.
Case–control biomarker discrimination capacity (AUC 
in Table 4) for the 15 biomarker set was high, as evidenced 
TaBle 5 | logistic and non-parametric regression for number of 
abnormally scored functional domains within the 15 biomarker set.
scored number of abnormal 
functional domains
0 1 2 3 4 5
% Predicted risk on logistic 
regression analysis
0.97 6.13 30.32 74.37 95.08 99.23
% Predicted risk on non-parametric 
(Lowess) regression analysis
0 3.7 38.88 66.22 88.48 100
Logistic regression R2 (Nagelkerke) = 0.752 and non-parametric (Lowess) regression 
R2 = 0.626.
TaBle 6 | Fivefold cross-validation results.
Fold no. Obs Population prevalence 
parameters
% sensitivity % specificity rOc area Odds ratio % PPV* % nPV*
1 28 0.35 78.6 92.9 0.857 47.7 3.7 99.9
30 78.6 92.9 0.857 47.7 82.5 91.0
2 26 0.35 84.6 92.3 0.855 66 3.7 99.9
30 84.6 92.3 0.885 66 82.5 93.3
3 28 0.35 85.7 64.3 0.750 10.8 0.8 99.9
30 85.7 64.3 0.750 10.8 50.7 91.3
4 26 0.35 92.3 92.3 0.923 144 4.0 100.0
30 92.3 92.3 0.923 144 83.7 96.6
5 26 0.35 84.6 92.3 0.885 66 3.7 99.9
30 84.6 92.3 0.885 66 82.5 93.3
Scored 15 biomarker set 134 0.35 85.1 86.6 0.858 36.7 2.2 99.9
30 85.1 86.6 0.858 36.7 73.1 93.1
Results are reported across prevalence values that may be clinically encountered, 0.35% prevalence = mean prevalence for schizophrenia (applicable to screening) within the 
Australian population, where 12 monthly MEAN schizophrenia prevalence is estimated as equivalent to 0.35/100 (0.35%), 30% prevalence = estimated prevalence rate among a 
clinical population (where expected conversion rate to schizophrenia is 30–35% at 1-year follow-up) (89).
*Percent positive predictive value and negative predictive value.
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examination of stress-related symptoms 
in relationship to risk-Predictor Variables
Spearman’s correlates were examined in relationship to stress-
related SIRs for anxiety, tension, and dissociation symptoms 
(see Statistical Analysis). The highest correlate strength for the 
symptom of anxiety was found for deficits in auditory processing 
domains of dysfunction [auditory domain (imputed) (n = 224, 
rho = 0.553, P = 0.000)]. For the symptom of tension, highest cor-
relate strength was obtained for deficits in both auditory domain 
(n = 124, rho = 0.409, P = 0.000) and high catecholamine domain 
(n = 133, rho = 0.408, P = 0.000).
Low competing words score (as a % of pass score) is an index 
of dichotic listening disorder. Symptoms of dissociation, such as 
experiencing “blank periods,” and “unreal feelings,” held interest-
ing highest correlates for this particular ROC variable. The disso-
ciative symptom of experiencing “blank periods” also correlated 
to low competing word score (n = 124, rho = 0.210, P = 0.019) in 
a setting where it also held significant correlates for the auditory 
and visual domains (imputed). In this context, the dissociative 
symptom of experiencing “unreal feelings” also correlated to both 
low competing word score (n = 124, rho = 0.212, P = 0.018) and 
with significant correlates in auditory and biochemical nutrition 
domains. There was a negative correlation between experiencing 
“unreal feelings” and histamine levels (n = 134, rho = −0.230, 
P = 0.004), which is further discussed below.
DiscUssiOn
Outcome measures that form the primary set of 15 biomark-
ers in this study are derived from easily procurable laboratory 
tests, inexpensive equipment, and simple-to-apply assessment 
methods that can be conducted in a 45-min consultation in an 
everyday clinical setting with low ambient noise.
The 21 biomarker set brings together an accumulation of 
ROC-defined biomarkers from several domains of biological 
and neurophysiological logical inquiry. It includes biomark-
ers for oxidative stress (HPL/creatinine) and nutrition-related 
by an AUC value of 0.952 associated with an accuracy index 
of 87%. The 21 biomarker set had an AUC of 0.95 and an 
accuracy index of 74%. Comparison between case-detection 
performance for data imputed and non-imputed data sets also 
revealed minimal difference (Section S12 in Supplementary 
Material).
Comparison of fivefold cross-validation parameters, with 
the original 15 biomarker set, demonstrated maintenance of 15 
set parameters for AUC, sensitivity, and specificity (Table  6). 
Moreover, the validity of these parameters was confirmed across 
a range of clinically useful schizophrenia population prevalence 
levels. This process provided the 15 biomarker set with a higher 
sensitivity value of between 85 and 92%. This process demon-
strated that the original tallied 15 biomarker set is stable, and its 
regression results are not unduly optimistic.
When the individual ROC variables were appraised against 
functional rating data using Spearman’s correlation matrix 
(Table 7), particularly high correlates were demonstrated for 
a number of biomarkers in relationship to outcome measures 
for severity (CGI and SIR), disability (GAF and SOFAS), and 
cost-care burden (disability pension requirement and hospital 
admission rate), at 95% level of significance. Notably, strong 
correlates were found between abnormalities in the visual 
and auditory domains and disability, social dysfunction, hos-
pitalization rate, disability support requirement, and severity 
measures.
TaBle 7 | spearman correlations (in descending order of strength), for 15 and 21 biomarker sets and their functional domains, with separate functional 
measures of disability and severity.
Domains (5 domains) 15 
biomarker set 
(imputed)
Visual auditory high 
catecholamine
Biochemistry–
nutrition
Oxidative stress 
(hPl/creatinine)
Middle ear (6 domains) 21 
biomarker set 
(imputed)
Case versus control 525 0.770 0.730 0.650 0.598 0.458 0.339 0.340 0.775
Symptom intensity rating (SIR) for 
psychosis
0.697 0.624 0.583 0.467 0.404 0.327 0.377 0.636
SOFAS ROC 0.752 0.729 0.632 0.591 0.415 0.312 0.341 0.758
GAF ROC 0.770 0.745 0.618 0.562 0.415 0.315 0.328 0.742
CGI ROC 0.754 0.729 0.636 0.591 0.415 0.312 0.341 0.761
Hospital admission rate 0.830 0.766 0.608 0.583 0.403 0.421 0.300 0.748
Disability pension requirement 0.677 0.608 0.530 0.460 0.309 0.296 0.212 0.609
Model domain case versus 
control
sOFas 
rOc
gaF rOc cgi rOc hospital 
admission rate
Disability 
pension
symptom intensity 
rating (sir)
15 biomarker set (5 domains) 0.770 0.752 0.770 0.754 0.830 0.677 0.697
Visual domain 0.650 0.632 0.618 0.636 0.608 0.530 0.624
Auditory domain 0.650 0.632 0.618 0.636 0.608 0.530 0.583
High catecholamines 0.598 0.591 0.562 0.591 0.583 0.460 0.4677
Biochemistry–nutrition domain 0.458 0.415 0.415 0.415 0.403 0.309 0.404
Middle ear domain 0.340 0.341 0.328 0.341 0.300 0.212 0.377
Oxidative stress (HPL/creatinine) 0.339 0.312 0.315 0.312 0.421 0.296 0.327
21 biomarker set (6 domains) 0.775 0.758 0.742 0.761 0.748 0.609 0.636
All rho values are at 95% level of confidence. For rho ≥0.350, P ≤ 0.0001. SOFAS, Social and Occupational Functioning Assessment Scale; GAF, Global Assessment of Function 
Scale; CGI, Clinical Global Index (of Severity). Hospital admission rate as determined by number of admissions divided by duration of illness and disability pension receipt, as indices 
of cost burden.
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biochemistry with intra- and extracerebral visual and auditory 
function markers.
Though internally validated, the utility of these findings has 
several caveats. First, substance abuse is a common concurrent 
feature of psychosis presentations in the clinical context; there-
fore, these assessments are valid in the setting of a non-active 
drug use history and ideally, a negative drug screen result. Second, 
these results require validation in larger samples, including other 
mental illness states, at other sites.
Discovered biomarkers represent a number of discrete sensory 
disorders, such as dichotic listening disorder, sensory processing 
delay disorders, distance visual acuity disorder, and inner ear 
dysfunction. Though it would therefore be remarkable if such 
discrete, subclinical disorders did not occupy at least a part of the 
etiological substructure of the condition that is recognized at its 
clinical surface as functional psychosis, drawing meaning from a 
biomarker cannot be automatically assumed. Indeed, meaningful 
explanation and predictive modeling are two different goals of 
research and biomarkers are mathematically derived parameters 
which of themselves cannot denote an etiological meaning for the 
condition they detect. Therefore, the following discussion of the 
meaning and dynamics of some of the biomarkers discovered in 
this study is supplied for reader’s interest, with further explana-
tions to be found in previous study reports (12).
elevated catecholamines and the Meaning 
of compound Biomarker results
ROC analysis-derived cutoff values for elevated DA, NA, and 
AD levels indicated that an excess state of these catecholamines 
was highly discriminative for functional psychosis. In keeping 
with other literature concerning DA and noradrenergic activity 
in schizophrenia, these findings may reflect stress-activated 
hypothalamic–pituitary–adrenal (HPA) axis activation in psy-
chosis (48–54).
In this study, we were not able to access serotonin level assays 
as these are only available under strict conditions related to diag-
nosis of serotonin-releasing gastrointestinal tumors. However, 
our interest in exploring the relationship of DA to serotonin’s 
metabolite 5HIAA is because serotonin (5HT) and DA have 
somewhat reciprocal roles in the brain (55). In this regard, 
these biomarker results for DA ×  5HIAA, seemingly indicate 
that elevated DA in functional psychosis is exacerbated by low 
serotonin, such as might occur with excess serotonin metabo-
lism, and accompanying increased excretion of 5-HIAA. Yet 
because the discrimination capacity of this combined biomarker 
(DA × 5HIAA) did not exceed that for elevated DA alone, it was 
not fitted into the model. It can, nevertheless, be viewed as an 
interesting finding, pointing toward further dynamics at work 
within the biochemical framework of schizophrenia. That said, 
the actual reliability of 5HIAA itself as an isolated marker separate 
from a serotonin level or a serotonin precursor l-tryptophan level 
must be considered dubious. Since serotonin is synthesized in the 
gastrointestinal tract, its levels may vary with diet. Theoretical 
uncertainty about the meaning of 5-HIAA also arises because of 
the diversion of the serotonin precursor molecule l-tryptophan 
away from serotonin synthesis and into the kynurenate pathway, 
under inflammatory conditions that have also been implicated in 
schizophrenia (56). Since we did not have resources to co-inves-
tigate inflammatory markers in this study and our urine samples 
for kynurenic pathway metabolites have not yet been assayed, we 
are not in a position to comment in any reliable manner on the 
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possible dynamic significance of the compound (DA × 5-HIAA) 
biomarker discovery, except to say that in the absence of inflam-
mation, it may reflect a conjoint tendency toward elevated DA 
levels and increased serotonin metabolism and excretion in a 
study setting where both DA and serotonin metabolites (HVA and 
5HIAA, respectively) were found to form ROCs of low yet valid 
significance. In a setting where research literature reports that the 
stimulating effect of cortically elevated DA relies on serotonin for 
a contrasting dampening effect (55), high serotonin metabolism 
with related low serum serotonin levels might help to explain the 
overstimulating effects of DA within the cerebral cortex.
Since MHMA is the direct metabolite of noradrenalin, the 
significant spare ROC findings of NA/MHMA and AD/MHMA 
and their high correlative relationships to NA and AD in this 
study imply that metabolism of NA and AD is compromised in 
this sample of patients with diagnoses representative of func-
tional psychosis (see Model Validation and biochemistry map in 
Section S1 in Supplementary Material). Metabolism of NA and 
AD is carried out by the enzyme monoamine oxidase (MAO); 
so, it can be surmised that MAO activity is compromised in our 
patient sample, a finding which is supported by literature accounts 
of this enzyme’s inhibition in schizophrenia and schizoaffective 
disorder (57).
Findings of low folate [a contributor to methylation and 
S-adenosylmethinine (SAMe) formation], together with elevated 
(NA and histamine), carry the implication that one-carbon cycle 
methylation is compromised in our sample of patients. SAMe 
unavailability with S-adenosylhomocysteine (SAH) elevation 
inhibits catechol-O-methyltransferase (COMT) catecholamine 
metabolism, providing an explanation for the elevated catecho-
lamine findings in this study (Section S1 in Supplementary 
Material). This explanation is supported by the study finding of 
a low, significant ROC curve for histamine, implying that SAMe 
might be lower than normal and SAH higher than normal within 
our patient sample. This occurs because SAMe is a required cofac-
tor for histamine metabolism by histamine N-methyltransferase 
(HNMT), and SAH also inhibits this reaction. Therefore, low 
global methylation may contribute to backed-up, unmetabolized, 
and elevated catecholamines in our patient sample. In an attempt 
to offset this situation, NA can also act as a methyl donor for 
histamine metabolism by HNMT, explaining why high serum 
histamine may be an unreliable surrogate marker for a low meth-
ylation state (22, 32, 58, 59).
Histamine has neurotransmitter properties that cause activa-
tion within the brain (60), while NA causes arousal, stress, and 
anxiety, and AD promotes fear and flight (61). It, therefore, seems 
either directly or indirectly because of low enzyme activity or 
through cofactor deficits that MAO inhibition, COMT inhibition, 
and inhibited histamine metabolism may together contribute to 
anxiety, fear, and over-arousal in our patient sample (22, 32, 57–60).
relationship of stress and Psychosis to 
sensory Timing and end-Organ 
Dysfunction
Due to past literature emphasis on the role of emotional stress 
in schizophrenia (62) and reported elevated catecholamines in 
schizophrenia and stress-related conditions (50–54), the finding 
of elevated catecholamines in this study led to cross-examination 
of stress-related symptoms of anxiety, tension, and dissociation 
in relationship to our ROC biomarker variables (see Statistical 
Analysis).
The particular finding that anxiety symptom intensity 
correlates more strongly to ROC biomarkers for auditory 
and visual domains of dysfunction than with elevated level of 
noradrenalin or adrenalin levels per  se, supports our theory 
that disturbed auditory and visual pathway transmission may 
itself serve as an intracerebral interoceptive cue that precipitates 
HPA activation (63), followed by heightened catecholamine 
synthesis and release. Indeed, our previously reported Lowess 
regression modeling confirmed a 76% predictive relation-
ship between visual domain biomarkers and catecholamine 
elevation (12). Such regression modeling also revealed that high 
threshold stapes amplitude was 79% predictive of longer stapes 
contraction duration, implying that an over-strong, over-brisk 
NA-driven stapes stress-response has potential to over-dampen 
and delay sound as it enters the cochlear. This effect may thus 
play a role in dampening and delaying sound transference into 
the brain. The brain’s subliminal recognition of such disturbed 
neural timing may then trigger an HPA initiated vicious cycle 
of further catecholamine synthesis and release (64). Though a 
moderate levels of NA encourage the brain to greater processing 
efficiency, when NA levels are gradually ramped up (or kindled) 
in this way, they eventually exert a detrimental effect on cortical 
sensory processing, resulting in sensory disconnection and a 
psychotic break (12, 65, 66).
It is also notable that sensory end-organ dysfunction from 
middle ear and long distance vision abnormalities were dis-
covered to contribute to the dysfunctional substrate of the 15 
biomarker – 5 domain set that formed the basis for regression 
analysis. Indeed, it is relatively easy to speculate that such visual 
and auditory impairments could well lead to anxiety and para-
noid suspicion upon the distant approach of an unknown person 
in community and clinical settings. Such findings highlight the 
critical importance of optimal patient access to specialist services 
for eye and ear assessment, so that visual and auditory end-organ 
dysfunction can be detected and remediated early in the course 
of the illness in order to curtail their contribution to fear and the 
catecholamine kindling process that leads on to sensory circuit 
disconnectivity and psychosis onset (12, 67).
Our stress-related findings (see Examination of Stress-Related 
Symptoms in Relationship to Risk-Predictor Variables) indicate 
that stress itself is a heterogeneous entity that takes different forms 
in psychosis according to the individual profile of dysfunction 
within each individual’s bio-neurophysiological substrate. In anxi-
ety, interoceptively cued sensory processing disorder predomi-
nates, but with tension, elevated catecholamines predominate.
With dissociative symptoms however, there are contrasting 
negative correlates for histamine levels occurring in the absence 
of any correlates for elevated catecholamines. This latter effect 
may be explained by high methylation with inversely low hista-
mine (68), in which case we theorize that high SAMe levels and 
over-active COMT-related catecholamine metabolism leads to 
depleted catecholamine levels that challenge adrenal capacity 
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for resynthesis resulting in reduced catecholamine release and 
so-called “adrenal fatigue” syndrome (69).
Dichotic listening Disorder, stress, and 
Functional Psychosis
Dichotic listening disorder, as evidenced by high competing 
words discrepancy (Section S5 in Supplementary Material) 
(expressed as percent of normative score for age), was a 
notable biomarker within the 15 biomarker set (n  =  124, 
AUC = 0.799, OR = 10.7, for P < 0.0001). Dichotic listening 
disorder has a known relationship to metabolic damage to the 
corpus callosum circuits that is related to hypoconnectivity 
and schizophrenia (70–72), and this intracerebral condition 
may be a strong target for remediation in schizophrenia and 
schizoaffective disorder.
Biochemistry and nutrition
Stress-related, HPA-triggered increase in catecholamine synthe-
sis can draw down on l-DOPA synthesis, which utilizes cofactor 
vitamin B6 that is also required for glutathione synthesis and 
its prevention of oxidative stress (Section S1 in Supplementary 
Material). As previously explained, deficits in precursor folate 
reserves can reduce downstream SAMe production, and low 
SAMe and higher SAH levels inhibit COMT activation and 
raises catecholamine levels further. Catecholamines, in turn, lead 
to excessive draw down on vitamin D reserves required to offset 
their effects on parathyroid hormone (12, 73). Undoubtedly, 
maternal dietary deficiency and dietary deficiency that accom-
panies the chaotic lifestyle of psychosis contribute to this effect 
(74, 75). This is, however, a wide and complex research area that 
requires further consideration and longitudinal therapeutic trials 
designed to resolve how readily cognitive and sensory processing 
deficits can be reversed by targeted supplement therapy (76). 
Certainly, it is within the clinical experience of this author that 
psychosis and affective states can be considerably ameliorated 
by including carefully targeted adjunctive biochemistry supple-
ments in a personalized treatment approach. Emerging reports in 
the research literature also attest to possible benefits from methyl 
folate supplementation to boost methylation (77). Beneficial 
use of n-acetyl cysteine for treatment of oxidative stress is also 
reported (78, 79).
limitations
Methodologies for discovering novel biomarkers and presenting 
these in models of disease pathophysiology remain in evolution 
and all bring a new point of view that should be globally con-
sidered (42). Though case–control study designs have inherent 
susceptibility to prevalence and selection bias (80), they are 
allowable for discovery and diagnostic accuracy studies (81) and 
have a respectable record when used to detect low prevalence 
disorders, such as schizophrenia (82). Participant refusal rate of 
25% for patients and controls alike may have created sufficient 
random effect to offset selection bias.
The impact of the exclusion criteria on the number of subjects 
in the study also brings into question the broader applicability 
of the model, particularly with regard to particular medication 
exclusions and substance use exclusion (83). However, it is envis-
aged that the model’s use is less likely to be required for patients 
already established on Clozapine or Olanzapine and is more likely 
to be used to for early diagnostic confirmation or population 
screening.
Despite our attempts to isolate SSRIs from the study sample, 
three patients had their data analyzed while still retained on these 
medications. However, this would make our findings even more 
significant, since the overall effect of SSRIs and SNRIs was to 
mask elevated catecholamine levels, sensory processing deficits, 
and abnormal middle ear outcome measurements. Both sodium 
valproate and quetiapine medication were not disallowed in 
this study and these agents have both been associated with high 
catecholamine levels in animal studies (84, 85). In the case of 
valproate, we theorize that sodium valproate promotes GABA 
synthesis from excess glutamate left over from NMDA hypo-
function that occurs in response action in GABA promotion, 
which mops up excess glutamate related to NMDA hypofunction 
that occurs in a reciprocal response to elevated DA levels (86). 
Quetiapine is a second-generation antipsychotic that has affinity 
for DA type 2 receptors, histamine type 1 receptors, and alpha 
1 and 5HT receptors, related to anxiety inhibition. Since NA 
stimulates alpha-1 receptors (87) and quetiapine blocks these 
receptors, it is theoretically possible that quetiapine and other 
DA-blocking antipsychotic medications that bring about their 
antipsychotic effects through receptor blockade might collater-
ally increase residual volume transmission of catecholamines in 
the extracellular cerebral space (88). If this is so, then elevated 
histamine levels residual to histamine receptor blockade by 
quetiapine might also be explicable through such volume trans-
mission dynamics.
Scoring and collapsing the data through multiple ROC 
analyses and later regression analysis have potential for loss of 
useful information and some data strength. Disease prevalence 
value was also set low in formulating the model, resulting in a low 
PPV values. Fortunately, this effect was found to be unimportant 
on fivefold cross-validation. Odds ratio calculations made in 
the context of a cross-sectional case–control design have been 
reported to yield results that may be inflated up to three times by 
prevalence bias (89). In this study, OR calculations endured even 
after the shrinkage factor of 3 had been applied to adjust for this 
possibility.
As mentioned in Section “Characteristics of Residual and 
Compound ROC Variables,” the selection of biomarker combina-
tions, such as DA × 5HIAA, NA/MHMA, and histamine + ele-
vated noradrenalin, was based upon their imputed meaning 
within the nutritional biochemistry pathways of interest (see 
Dichotic Listening Disorder, Stress, and Functional Psychosis). 
Though support for the etiological significance of biomarkers 
in this study can be drawn from previous global translational 
findings (12) and implied from the number of biomarkers that 
represent discrete brain disorders within the model itself, a 
mathematical case-detection model does not possess inherent 
content validity.
A further limitation of the case–control discovery design is that 
the relevance of discov ered biomarkers to other forms of mental 
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illness is unknown. Therefore the optimal means for replicating 
and validating this project’s discovery biomarkers is via a large, 
well-characterized, prospective, and multi-site clinic trial on a 
series of consecutive patients with other mental illness diagnoses. 
Blinded assessors and an emphasis on collecting longitudinal 
data from ultra high risk for psychosis medication-naive subjects 
as well as for participants with a variety of other mental illness 
is required. Issues of the effect of chaotic lifestyle and traumatic 
stress arising from, or embedded within, the psychosis condition 
itself also require further research.
cOnclUsiOn
These findings have screening and case-confirmation potential 
for conditions, such as schizophrenia and schizoaffective psycho-
sis, as a diagnosis of functional psychosis can be predicted from 
the results of a 45-min clinic consultation using easily accessed 
laboratory tests and simple-to-apply equipment.
Combining 21 biomarkers derived from outcome measures 
from well-characterized patients and controls into clinically 
accessible biomarker sets allows better statistical outcomes than 
using single biomarkers alone. These biomarker sets contain 
markers representative of several domains of biological, cogni-
tive, and neurophysiological inquiry – in particular for elevated 
catecholamines, oxidative stress, nutritional and catecholamine-
related biochemistry, visual and auditory processing, and visual 
end-organ sensory function. The unimputed 15 biomarker set has 
good case discrimination with 84% sensitivity and 90% specificity 
for case detection and screening purposes. The 21 biomarker set 
containing 6 additional parameters of middle ear dysfunction, 
has increased sensitivity for case confirmation. Therefore, the 
model has potential use in settings where psychosis is suspected, 
yet 15 biomarkers alone do not provide sufficiently strong results 
for case risk or case certainty.
Though predictive case capacity for biomarkers cannot be 
directly equated with etiology, many of the biomarkers discov-
ered represent discrete potentially remediable biological vulner-
ability factors lying undetected within the fabric of functional 
psychosis. In particular, dichotic listening disorder may be a 
strong target for remediation in schizophrenia and schizoaffec-
tive disorder. Also, subclinical sensory end-organ dysfunction 
that has often been viewed as a mere comorbidity appears to 
be integral to the psychosis process itself. Such findings have 
potential to steer clinicians in the direction of objective testing, 
increase rigor of clinical assessments, and provide access for 
patients to specialist services in order to correct unmet needs. 
In due course, such changes might positively influence patient 
outcomes by assisting case monitoring, relapse prevention, 
treatment-resistant management, and judiciously sequenced, 
targeted treatment.
Implications from correlative findings for biomarkers with dif-
ferent forms of stress-related symptoms unveil a heterogeneous 
mix of sensory end-organ dysfunction and biochemically dam-
aged, pre-aged sensory processing circuits. These pathologies 
are thought to trigger catecholamine elevation in an escalating 
kindling process, culminating in different forms of anxiety with 
disconnectivity, dissociation, and psychosis.
Ratings for disability and severity that correlate strongly to 
biomarkers in the model imply that targeted treatment of these 
biomarkers has potential to reduce hospitalization rate, disability, 
severity of symptoms, and cost-care burden for families, care pro-
viders, and the community alike. Such findings require further 
research and invite a new understanding of the biological fabric 
and phenomenology of functional psychosis.
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